GlassScriptPhysician profile
Filomeno P Gonzalez
NPI 1376549204
$4,844.86
in general payments reported to CMS, 2019-2025
38 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.72 · 2020: $431 · 2021: $1,380 · 2022: $1,477 · 2023: $1,275 · 2024: $77.61 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $612.97 | 2020-2023 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $412.81 | 2020-2023 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $365.74 | 2021-2023 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $360.16 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $333.22 | 2022-2023 | |
| Abbott Laboratories | $309.73 | 2021-2024 | Proclaim |
| Amarin Pharma, INC. | $231.40 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $227.38 | 2022 | |
| Abbvie INC. | $221.99 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.70 | 2021-2023 | Xifaxan |
| Medtronic, INC. | $171.46 | 2021-2022 | |
| Amgen INC. | $163.86 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $162.95 | 2020-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $136.56 | 2021-2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $128.25 | 2025 | Caplyta |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Filomeno Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.